Are unsatisfactory outcomes after concurrent chemoradiotherapy for locally advanced non-small cell lung cancer due to treatment-related immunosuppression?
Overall survival after radiotherapy (RT) for locally advanced non-small cell lung cancer (LA-NSCLC) continues to be far from optimal despite recent progress with the use of adjuvant immune checkpoint inhibitors, which has resulted in a 10% increase (from 56% to 66%) in the two-year overall survival (OS) rates [1,2]. Of particular interest, cardio-pulmonary dose has been found to correlate negatively with OS in various LA-NSCLC series, including RTOG 0617 [3 –8]. The primary hypothesis addressed to this correlation has been radiation-induced cardiac toxicity, and a number of studies have thereafter established an association between a range of symptomatic cardiac toxicities and cardiac dose [9–14].
Source: Radiotherapy and Oncology - Category: Radiology Authors: Maria Thor, Margaret Montovano, Alexandra Hotca, Leo Luo, Andrew Jackson, Abraham J. Wu, Joseph O. Deasy, Andreas Rimner Tags: Original Article Source Type: research
More News: Cancer | Cancer & Oncology | Cardiology | Heart | Lung Cancer | Non-Small Cell Lung Cancer | Radiology | Study | Toxicology